Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY3127760 · 1 trial · 1 indication
Data presented are the number of participants who experienced SAEs considered by the investigator to be related to study drug administration. A summary of SAEs and all other non-serious Adverse Event(s) (AEs), regardless of causality, is located in the Reported Adverse Event module.
| Arm | Type | Description |
|---|---|---|
| LY3127760 (Single) | EXPERIMENTAL | Single oral dose of up to 900 milligram (mg) LY3127760 administered in up to 3 of 3 study periods. |
| Placebo (Single) | PLACEBO_COMPARATOR | Single oral dose of placebo administered in up to 2 of 3 study periods. Placebo matches LY3127760 in appearance. |
| LY3127760 (Multiple) | EXPERIMENTAL | Multiple ascending oral doses of up to 900 mg LY3127760 administered once or twice daily (QD or BID) for 28 days. |
| Placebo (Multiple) | PLACEBO_COMPARATOR | Multiple oral doses of placebo administered QD or BID for 28 days. Placebo matches LY3127760 in appearance. |
| Celecoxib (Multiple) | ACTIVE_COMPARATOR | Multiple oral doses of 400 mg celecoxib administered QD for 28 days. |
| Name | Type | Description |
|---|---|---|
| LY3127760 | DRUG | Administered orally |
| Celecoxib | DRUG | Administered orally |
| Placebo | DRUG | Administered orally |
Inclusion Criteria: * Overtly healthy males or females as determined by medical history and physical examination * Male participants agree to use a reliable method of birth control during the study and 3 months following the last dose of the investigational product * Female participants not of chil...
LY3127760 is an investigational small molecule being developed by Eli Lilly and Company. It is currently in Phase 1 clinical development, studied in healthy volunteers. The drug has completed one clinical trial with 80 participants.
LY3127760 is a small molecule, but its specific molecular target has not been disclosed. The drug is being studied in healthy volunteers to evaluate its safety and tolerability, though its mechanism of action is not publicly detailed.
LY3127760 is developed by Eli Lilly and Company, a pharmaceutical company traded on the NYSE under the ticker symbol LLY. The drug is currently in Phase 1 clinical development.
LY3127760 is in Phase 1 clinical development. It is an investigational drug, not yet approved by regulatory authorities. One Phase 1 trial has been completed, and the drug is no longer in active clinical trials.
LY3127760 has one completed clinical trial, NCT01968070, titled "A Study of LY3127760 in Healthy Participants." This Phase 1 study enrolled 80 healthy volunteers in the United States and was placebo-controlled, randomized, and double-blind.
LY3127760 is not FDA approved. It is an investigational drug that has completed a Phase 1 clinical trial in healthy volunteers. The drug is still in clinical development and has not been approved for any medical use.